{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134777","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.984587+00:00","generated_at":"2026-06-02T07:40:07.058664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"XOMA Q1 net loss $8.6M; FDA approves OJEMDA triggering $9M milestone","bullets":["Q1 revenue $1.5M (vs $0.4M YoY) on $1M AVEO milestone; net loss $8.6M (vs $9.8M YoY).","FDA approved Day One's OJEMDA; XOMA earned $9M milestone and will receive mid-single digit royalties.","Acquired Kinnate Pharmaceuticals for $2.5879/share + CVR; adds at least $9.5M non-dilutive capital.","Expanded royalty portfolio: economic interests in DSUVIA, XACIATO, Ovaprene (Ph3), and Sildenafil Cream.","Launched first $50M stock buyback; cash $142.4M at March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134777","json":"https://secwatch.observer/filing/0001193125-24-134777.json","markdown":"https://secwatch.observer/filing/0001193125-24-134777.md","text":"https://secwatch.observer/filing/0001193125-24-134777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/0001193125-24-134777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/d841331d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:40:07.058664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8c96b51a26da5d1a74a64142453208e4f463ba5","claim":"XOMA Royalty Corp reported the quarter ended March 31, 2024 results: revenue $1.5 million, net income $8.6 million.","evidence_excerpt":"XOMA recorded total revenues of $1.5 million for the first quarter of 2024, which included a $1.0 million milestone payment received from AVEO Oncology, as compared with $0.4 million in the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/0001193125-24-134777-index.htm","confidence":0.88,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.5 million"},{"label":"Net income","value":"$8.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}